Free Trial
NASDAQ:BTTX

Better Therapeutics Earnings Date & Estimates

Better Therapeutics logo
$0.0001 0.00 (0.00%)
As of 11/3/2026 09:46 AM Eastern

Better Therapeutics is estimated to report earnings on Thursday, November 12, 2026.

What Analysts Expect from Better Therapeutics

Better Therapeutics is expected to post earnings of -$0.21 per share on revenue of $6.58 million. Better Therapeutics has beaten the consensus EPS estimate in 4 of its last 6 quarters.

Consensus Estimates

Consensus EPS
-$0.21
Expected Revenue
$6.58 million

Recent Track Record

Last Reported
Q3 2023
Last Quarter EPS
-$0.15
EPS Beat Rate
4 of last 6 quarters

Better Therapeutics Earnings FAQ

Better Therapeutics (NASDAQ:BTTX) is estimated to report earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Better Therapeutics to post earnings of -$0.21 per share for the quarter.

The consensus revenue estimate for Better Therapeutics is $6.58 million for the quarter.

Better Therapeutics Earnings Headlines

BTTX Better Therapeutics, Inc. - Seeking Alpha
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
Janux Therapeutics Inc (JANX) Receives a Buy from BTIG
See More Better Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Better Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Better Therapeutics and other key companies, straight to your email.

About Better Therapeutics

Better Therapeutics (NASDAQ:BTTX) was a digital therapeutics company focused on developing prescription software designed to address chronic metabolic and cardiometabolic conditions. Its approach combined behavioral therapy, personalized digital coaching and clinical content delivered through software intended for use alongside standard medical care.

The company’s lead product, AspyreRx, formerly known as BT-001, was authorized by the U.S. Food and Drug Administration in 2023 as a prescription digital therapeutic for adults with type 2 diabetes. The software was designed to support behavior change and help patients manage their condition in conjunction with traditional treatment.

Better Therapeutics was based in the United States and primarily targeted the U.S. healthcare market. Following the FDA authorization of AspyreRx, the company announced a strategic review and subsequently reported a wind-down of operations. Information about its current commercial activities and leadership is limited.

View Better Therapeutics Profile